Aller au contenu principal
Accès ouvert déclaré 2025 article

Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe

3Citations signalées, ce qui n’est pas une note de qualité
51Institutions déclarées
12Pays d’affiliation déclarés

Rattachement africain : nl, us, de, pt, fr, at, es, lu, be, gb, ca, it. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

ABSTRACT: Patient-reported outcomes (PROs) give direct insights into the treatment's impact on patient's life and complement clinical outcomes. However, since the advent of chimeric antigen receptor T-cell therapy (CAR-T), PROs have been underreported. Particularly, little is known about long-term health-related quality of life (HRQoL) and dimensions such as mental- and social well-being, working life, and financial burden. Therefore, we evaluated multidimensional PROs in a cross-sectional study among European patients who received CAR-T for hematologic malignancies. Patients completed validated questionnaires (EQ-5D-5L/EORTC-QLQ-C30/PCL-5/modified-iPCQ) and ad hoc items on treatment experiences, unmet care needs, and HRQoL. The survey was available online (January-October 2023) in 7 languages. Outcomes were compared with the European general population, a matched CAR-T-naive cohort with hematologic malignancies and across subgroups, using established thresholds for clinically important differences/problems and regression models. From 10 European countries, 389 patients participated (>1 year post-CAR-T: 56%). Mean EQ-VAS was 73.1 (standard deviation, 18.5). HRQoL was similar or better than reference cohorts, except for role-, social-, and cognitive-functioning. Physical-functioning problems were most frequently reported (41%), particularly by women, older individuals, and those who experienced neurotoxicity. The latter subgroup also reported more cognitive- and social-functioning problems. Anxiety regarding disease recurrence (76%), infections (66%) and long-term side effects (59%) was common. Among working-age patients, 72% could continue paid work after CAR-T. Younger patients (32%) reported more financial difficulties than older patients (9%). This study shows favorable general HRQoL after CAR-T compared with reference cohorts. However, a notable proportion of patients experienced problems in physical-, mental- and social well-being. We identified high-risk subgroups and care needs that should be addressed during follow-up.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe
Date Crossref
11/12/2025
Éditeur
American Society of Hematology
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Amsterdam NeuroscienceAmsterdam University Medical CentersInternational Myeloma FoundationCancer Center AmsterdamAmsterdam University of Applied SciencesUniversity of AmsterdamErasmus University RotterdamNetherlands Comprehensive Cancer OrganisationAugenklinik Universitätsklinikum WürzburgInstituto Português de Oncologia Francisco GentilEuropean Hematology AssociationInstitut National du CancerRUAG (Germany)International Society for Optics and PhotonicsMedical University of ViennaHospital Clínic de BarcelonaConsorci Institut D'Investigacions Biomediques August Pi I SunyerUniversity of LuxembourgLuxembourg Institute of Science and TechnologyArbed (Luxembourg)HOPE ClinicLymphoma Study AssociationEuropean Federation of Allergy and Airways Diseases Patients AssociationsAdvocates for YouthVrije Universiteit AmsterdamAntwerp University HospitalUniversité Paris CitéAssistance Publique – Hôpitaux de ParisHôpital Saint-LouisCellular Therapeutics (United Kingdom)European Society for Blood and Marrow TransplantationUniversity College London Hospitals NHS Foundation TrustInstitute of Infection and ImmunityUniversity College LondonInstitut d'Investigació Biomédica de BellvitgeInstitut Català d'OncologiaInsermGroupe de Recherche en Psychologie SocialeDélégation Régionale Auvergne-Rhône-AlpesUniversity Medical Center GroningenErasmus HospitalFIT Consulting (Italy)Institut de Relations Internationales et StratégiquesLyon 1 UniversitéCentre National de la Recherche ScientifiqueHospices Civils de LyonLaboratoire de Biométrie et Biologie EvolutiveUniversitäts-Kinderklinik WürzburgKoenig & Bauer (Germany)National Center for Tumor DiseasesFraunhofer Institute for Cell Therapy and Immunology

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

CAR-T cell therapy researchCancer-related cognitive impairment studiesFrailty in Older Adults

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.